Company Information

Hikma Pharmaceuticals PLC purchased a total of 372,440 of its ordinary shares through J.P. Morgan Securities plc between May 27 and May 29, 2026, as part of the second tranche of its $250 million share repurchase programme. The shares were acquired at prices ranging from 1,462.0000 pence to 1,503.0000 pence per share and the Company intends to cancel them. Since the programme's launch on February 26, 2026, the Company has purchased 7,448,843 ordinary shares for a total cost of £98,579,451.68, resulting in 214,437,610 ordinary shares in issue and total voting rights after the announced cancellation.

RNS Metadata